Forest Laboratories entered into settlement agreement with a company that wanted marketing approval for a generic version of its blood pressure drug Bystolic.
The patent infringement suit was against Glenmark Generics Inc.
Under the settlement agreement, Glenmark will be able to start selling a lower-cost version of Bystolic about three months before the patents protecting the drug expire.
The drug is a member of the beta blocker family of medications that control high blood pressure by relaxing blood vessels and slowing heart rate.
Earlier this year Forest and Johnson & Johnson sued Glenmark and several other drugmakers.
Most of the lawsuits have been settled, but suits against Watson Pharmaceuticals Inc. and Amerigen Pharmaceuticals Ltd. have not been resolved.
Forest got about one-sixth of its total revenue from Bystolic in its latest fiscal quarter.
The company is also studying a drug that combines Bystolic with valsartan, an older blood pressure drug sold under the name Diovan.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Forest Laboratories
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity